Autonomix Medical Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$16.1MTTM through 30 Jun 2026
Free Cash Flow -$13.2MTTM through 30 Jun 2026
Margins
| Current |
|---|
Balance Sheet Health
Current Ratio4.85x
Cash & Equivalents$3.5M
Quality Metrics
Altman Z-Score-31.26
Piotroski F-Score2 / 9
Earnings-Beat Rate66.7%
Multi-Year Trend
RevenueFY2026: $0
Diluted EPSFY2026: $-2.32
Dividend
No dividend
Capital Allocation
R&D Spend$7.1M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Medical Devices | $0 | View detailsInitially focusing on pancreatic cancer pain as the first indication, with plans to expand into other nerve-related disorders such as hypertension and cardiology. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.